Maxygen deal with H. Lundbeck

MAXY granted H. Lundbeck (CSE:LUN) rights to a protein pharmaceutical to treat central nervous system (CNS) diseases. MAXY retains CNS rights in Asia, and global non-CNS rights, including cancer and i...